Citizens Jmp Has Lowered Expectations for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price decreased by equities research analysts at Citizens Jmp from $27.00 to $25.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s price objective indicates a potential upside of 269.82% from the company’s previous close.

Several other research firms have also recently issued reports on BCRX. Barclays decreased their price objective on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. Needham & Company LLC cut their price objective on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 26th. Finally, Zacks Research upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.33.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $6.76 on Wednesday. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -37.55 and a beta of 1.05. BioCryst Pharmaceuticals has a one year low of $6.00 and a one year high of $11.31. The stock’s fifty day moving average is $7.53 and its 200-day moving average is $8.69.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The firm had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. The business’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.07) earnings per share. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Insider Activity at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the sale, the director owned 65,352 shares in the company, valued at approximately $556,145.52. This represents a 51.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at approximately $32,000. New Age Alpha Advisors LLC purchased a new stake in BioCryst Pharmaceuticals in the 1st quarter worth about $62,000. Family Legacy Financial Solutions LLC purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth about $72,000. Allspring Global Investments Holdings LLC purchased a new stake in BioCryst Pharmaceuticals in the 1st quarter worth about $79,000. Finally, Farther Finance Advisors LLC lifted its stake in BioCryst Pharmaceuticals by 326.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 8,109 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.